Efficacy and Safety of Tofacitinib in Subjects With Active Ankylosing Spondylitis (AS)

NCT ID: NCT03502616

Last Updated: 2021-09-17

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

270 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-06-07

Study Completion Date

2020-08-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine if tofacitinib is safe and effective in subjects with active ankylosing spondylitis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ankylosing Spondylitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Tofacitinib

Group Type EXPERIMENTAL

Tofacitinib

Intervention Type DRUG

Oral administration twice per day

Placebo

Group Type PLACEBO_COMPARATOR

Tofacitinib

Intervention Type DRUG

Oral administration twice per day

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tofacitinib

Oral administration twice per day

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Has a diagnosis of Ankylosing Spondylitis (AS) based on the Modified New York Criteria for AS (1984).
* Must have a radiograph of SI joints (AP Pelvis) documenting diagnosis of AS.
* Has active disease despite nonsteroidal anti-inflammatory drug (NSAID) therapy or intolerant to NSAIDs.

Exclusion Criteria

* History of known or suspected complete ankylosis of the spine.
* History of allergies, intolerance or hypersensitivity to lactose or tofacitinib.
* History of any other rheumatic disease.
* Any subject with condition affecting oral drug absorption.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Pfizer

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Rheumatology Associates of North Alabama, PC

Huntsville, Alabama, United States

Site Status

Arizona Arthritis & Rheumatology Associates, P.C.

Gilbert, Arizona, United States

Site Status

Medvin Clinical Research

Covina, California, United States

Site Status

Rheumatology Center of San Diego PC

San Diego, California, United States

Site Status

University of California, San Francisco Medical Center

San Francisco, California, United States

Site Status

Robin K. Dore, MD, Inc.

Tustin, California, United States

Site Status

New England Research Associates, LLC

Bridgeport, Connecticut, United States

Site Status

Advanced Radiology

Stamford, Connecticut, United States

Site Status

Stamford Therapeutics Consortium

Stamford, Connecticut, United States

Site Status

Southcoast Research Center, Inc.

Miami, Florida, United States

Site Status

Millennium Research

Ormond Beach, Florida, United States

Site Status

Bluegrass Community Research, Inc

Lexington, Kentucky, United States

Site Status

Center for Rheumatology and Bone Research

Wheaton, Maryland, United States

Site Status

M3-Emerging Medical Research, LLC

Durham, North Carolina, United States

Site Status

Paramount Medical Research and Consulting, LLC

Middleburg Heights, Ohio, United States

Site Status

Oregon Health & Science University

Portland, Oregon, United States

Site Status

Altoona Center For Clinical Research

Duncansville, Pennsylvania, United States

Site Status

Articularis Healthcare Group, Inc d/b/a Low Country Rheumatology

Summerville, South Carolina, United States

Site Status

Precision Comprehensive Clinical Research Solutions

Colleyville, Texas, United States

Site Status

Adriana Pop-Moody MD - Clinic PA

Corpus Christi, Texas, United States

Site Status

Metroplex Clinical Research Center

Dallas, Texas, United States

Site Status

Clinical Research Unit

Houston, Texas, United States

Site Status

Investigational Drug Services

Houston, Texas, United States

Site Status

Memorial Hermann Hospital Imaging

Houston, Texas, United States

Site Status

Southwest Rheumatology Research LLC

Mesquite, Texas, United States

Site Status

Trinity Universal Research Associates, Inc.

Plano, Texas, United States

Site Status

Advanced Rheumatology of Houston

The Woodlands, Texas, United States

Site Status

Arthritis Northwest, PLLC

Spokane, Washington, United States

Site Status

Pacific Radiology,

Maroochydore, Queensland, Australia

Site Status

Rheumatology Research Unit Sunshine Coast

Maroochydore, Queensland, Australia

Site Status

Emeritus Research Pty. Ltd.

Camberwell, Victoria, Australia

Site Status

Melbourne Radiology Clinic

East Melbourne, Victoria, Australia

Site Status

SKG Radiology

Subiaco, Western Australia, Australia

Site Status

Western Cardiology

Subiaco, Western Australia, Australia

Site Status

RK Will Pty Ltd

Victoria Park, Western Australia, Australia

Site Status

Multiprofile Hospital for active treatment "Kaspela" EOOD

Plovdiv, , Bulgaria

Site Status

Diagnostic-Consulting Center XVII - Sofia

Sofia, , Bulgaria

Site Status

Medical Centre Synexus Sofia EOOD

Sofia, , Bulgaria

Site Status

G.R.M.O. (Groupe de recherche en maladies osseuses) Inc.

Québec, Quebec, Canada

Site Status

Centre de Recherche Musculo-Squelettique

Trois-Rivières, Quebec, Canada

Site Status

Guangdong Provincial People's Hospital

Guangzhou, Guangdong, China

Site Status

The Third Affiliated Hospital, Sun Yat-Sen University

Guangzhou, Guangdong, China

Site Status

The Second Affiliated Hospital of Zhejiang University School of Medicine

Hangzhou, Zhejiang, China

Site Status

The First Affiliated Hosptial of Wenzhou Medical University

Wenzhou, Zhejiang, China

Site Status

Rheumatology and Immunology Department, Shanghai Changzheng Hospital

Shanghai, , China

Site Status

Lekarna Rezidence Nova Karolina

Ostrava, , Czechia

Site Status

CCBR Ostrava s.r.o.

Ostrava, , Czechia

Site Status

BENU Lekarna

Pardubice, , Czechia

Site Status

CCR, Czech a.s.

Pardubice, , Czechia

Site Status

Lekarna Hradebni, s.r.o.

Uherské Hradiště, , Czechia

Site Status

Uherskohradistska nemocnice, a.s.

Uherské Hradiště, , Czechia

Site Status

Medical Plus s.r.o.

Uherské Hradiště, , Czechia

Site Status

CHRU de Tours, Hopital Trousseau

Tours, , France

Site Status

Qualiclinic K ft

Budapest, , Hungary

Site Status

Pest megyei Flór Ferenc Kórház, Reumatológia-és Fizioterápiás Osztály

Kistarcsa, , Hungary

Site Status

VITAL MEDICAL CENTER (VITÁL-MEDICINA Kft.)

Veszprém, , Hungary

Site Status

Barzilai Medical Center

Ashkelon, , Israel

Site Status

Geo Medical Sp. z.o.o Szpital Geo Medical

Katowice, , Poland

Site Status

Moja Przychodnia

Katowice, , Poland

Site Status

C.M. Silmedic Sp. z o.o.

Katowice, , Poland

Site Status

Malopolskie Badania Kliniczne Sp. z o.o. s.k.

Krakow, , Poland

Site Status

Samodzielny Publiczny Zaklad Opieki Zdrowotnej MSWiA

Krakow, , Poland

Site Status

Centrum Medyczne Plejady

Krakow, , Poland

Site Status

Centrum Medyczne LUX MED

Krakow, , Poland

Site Status

Malopolskie Centrum Medyczne S.C.

Krakow, , Poland

Site Status

Szpital Uniwersytecki w Krakowie, Zaklad Radiologii

Krakow, , Poland

Site Status

Top Medical

Lublin, , Poland

Site Status

Zespol Poradni Specjalistycznych REUMED, Wallenroda Filia nr 1

Lublin, , Poland

Site Status

NZOZ JAMED Pracownia Rentgenowska Jerema Antoszewski

Poznan, , Poland

Site Status

Prywatna Praktyka Lekarska Prof. UM dr hab. med. Pawel Hrycaj

Poznan, , Poland

Site Status

Klinika Alfa

Sochaczew, , Poland

Site Status

RCMed Oddzial Sochaczew

Sochaczew, , Poland

Site Status

Szpital Powiatowy w Sochaczewie

Sochaczew, , Poland

Site Status

Szpital Sw. Elzbiety, Mokotowskie Centrum Medyczne, Zaklad Diagnostyki

Warsaw, , Poland

Site Status

"Reumatika - Centrum Reumatologii" NZOZ

Warsaw, , Poland

Site Status

Centrum Medyczne Oporow

Wroclaw, , Poland

Site Status

Centrum Medyczne Medix

Wroclaw, , Poland

Site Status

Limited Liability Company Medical Center "Rheuma-Med"

Kemerovo, , Russia

Site Status

State Budgetary Healthcare Institution "Orenburg Regional Clinical Hospital"

Orenburg, , Russia

Site Status

Limited Liability Company "Sanavita"

Saint Petersburg, , Russia

Site Status

State Healthcare Institution "Regional Clinical Hospital"

Saratov, , Russia

Site Status

RSBHI "Smolensk Regional Clinical Hospital"

Smolensk, , Russia

Site Status

Limited Liability Company "BioMed"

Vladimir, , Russia

Site Status

Chonnam National University Hospital

Gwangju, , South Korea

Site Status

Inha University Hospital

Incheon, , South Korea

Site Status

Hanyang University Seoul Hospital

Seoul, , South Korea

Site Status

Ankara Universitesi Tip Fakultesi Ibn-i Sina Hastanesi

Ankara, , Turkey (Türkiye)

Site Status

Ankara Universitesi Tip Fakultesi, Ibn-i Sina Hastanesi

Ankara, , Turkey (Türkiye)

Site Status

Hacettepe Universitesi Tip Fakultesi, Ic Hastaliklari Anabilim

Ankara, , Turkey (Türkiye)

Site Status

Istanbul Universitesi Istanbul Tip Fakultesi, Ic Hastaliklari

Istanbul, , Turkey (Türkiye)

Site Status

Istanbul Universitesi Istanbul Tip Fakultesi

Istanbul, , Turkey (Türkiye)

Site Status

Marmara Univ. Istanbul Pendik Egitim ve Arastirma Hastanesi

Istanbul, , Turkey (Türkiye)

Site Status

Izmir Katip Celebi Univ Ataturk Egitim ve Arastirma Hastanesi

Izmir, , Turkey (Türkiye)

Site Status

Izmir Katip Celebi Univ. Ataturk Egitim ve Arastirma Hastanesi

Izmir, , Turkey (Türkiye)

Site Status

Kyiv City Clinical Hospital # 3, Rheumatology Department

Kyiv, , Ukraine

Site Status

Lviv Communal Clinical Hospital #4, Rheumatology department

Lviv, , Ukraine

Site Status

Military-Medical Clinical Center (Clinical Hospital with 200 beds) of State Border Guard Service of

Lviv, , Ukraine

Site Status

Ternopil University Hospital, Department of Rheumatology,

Ternopil, , Ukraine

Site Status

Vinnytsia Regional Clinical Hospital n.a. M.I.Pyrohov, rheumatology department,

Vinnytsia, , Ukraine

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Australia Bulgaria Canada China Czechia France Hungary Israel Poland Russia South Korea Turkey (Türkiye) Ukraine

References

Explore related publications, articles, or registry entries linked to this study.

Deodhar A, Akar S, Curtis JR, El-Zorkany B, Magrey M, Wang C, Wu J, Makgoeng SB, Vranic I, Menon S, Fleishaker DL, Diehl AM, Fallon L, Yndestad A, Landewe RBM. Integrated safety analysis of tofacitinib from Phase 2 and 3 trials of patients with ankylosing spondylitis. Adv Rheumatol. 2024 Dec 18;64(1):87. doi: 10.1186/s42358-024-00402-x.

Reference Type DERIVED
PMID: 39695887 (View on PubMed)

Gossec L, Walsh JA, Sengupta R, Bushmakin AG, Cappelleri JC, Yndestad A, Dina O, Cella D. Improvement of Fatigue in Patients with Ankylosing Spondylitis Receiving Tofacitinib: Analyses of a Phase 3 Randomized Controlled Trial. Rheumatol Ther. 2025 Feb;12(1):85-98. doi: 10.1007/s40744-024-00727-5. Epub 2024 Dec 13.

Reference Type DERIVED
PMID: 39671076 (View on PubMed)

Norton H, Sliwinska-Stanczyk P, Hala T, El-Zorkany B, Stockert L, Mundayat R, Wang L, Ritchlin CT. Tofacitinib Efficacy/Safety in Patients with Ankylosing Spondylitis by Baseline Body Mass Index: A Post Hoc Analysis of Phase 2/3 Trials. Rheumatol Ther. 2025 Feb;12(1):67-84. doi: 10.1007/s40744-024-00726-6. Epub 2024 Dec 5.

Reference Type DERIVED
PMID: 39636343 (View on PubMed)

Ogdie A, Kristensen LE, Soriano ER, Akar S, Sun Y, Gruben D, Fallon L, Kinch CD, Gladman DD. Efficacy and Safety of Tofacitinib in Patients with Psoriatic Arthritis or Ankylosing Spondylitis by Cigarette Smoking Status. Rheumatol Ther. 2024 Dec;11(6):1649-1664. doi: 10.1007/s40744-024-00711-z. Epub 2024 Sep 25.

Reference Type DERIVED
PMID: 39320582 (View on PubMed)

Deodhar A, Baraliakos X, Magrey M, Gensler LS, Thorat AV, Pemmaraju SK, Cadatal MJ, Nash P. Efficacy and Safety of Tofacitinib in Ankylosing Spondylitis by Baseline C-Reactive Protein Level: Post Hoc Analysis of Phase II and Phase III Clinical Trials. J Rheumatol. 2024 Aug 1;51(8):772-780. doi: 10.3899/jrheum.2023-1198.

Reference Type DERIVED
PMID: 38825359 (View on PubMed)

Navarro-Compan V, Deodhar A, Bahiri R, Bushmakin AG, Cappelleri JC, Rammaoui J. Time to improvement of pain, morning stiffness, fatigue, and disease activity in patients with ankylosing spondylitis treated with tofacitinib: a post hoc analysis. Arthritis Res Ther. 2024 May 24;26(1):105. doi: 10.1186/s13075-024-03313-w.

Reference Type DERIVED
PMID: 38790040 (View on PubMed)

Kristensen LE, Deodhar A, Leung YY, Vranic I, Mortezavi M, Fallon L, Yndestad A, Kinch CD, Gladman DD. Risk Stratification of Patients with Psoriatic Arthritis and Ankylosing Spondylitis for Treatment with Tofacitinib: A Review of Current Clinical Data. Rheumatol Ther. 2024 Jun;11(3):487-499. doi: 10.1007/s40744-024-00662-5. Epub 2024 May 2.

Reference Type DERIVED
PMID: 38696034 (View on PubMed)

Magrey M, Wei JC, Yndestad A, Bushmakin AG, Cappelleri JC, Dina O, Deodhar A. Relationships of Work Productivity and Activity Impairment With Patient-Reported Outcomes in Ankylosing Spondylitis: Results From Two Trials. Arthritis Care Res (Hoboken). 2024 Mar;76(3):359-365. doi: 10.1002/acr.25267. Epub 2024 Jan 5.

Reference Type DERIVED
PMID: 37909386 (View on PubMed)

Cella D, Lenderking WR, Chongpinitchai P, Bushmakin AG, Dina O, Wang L, Cappelleri JC, Navarro-Compan V. Functional Assessment of Chronic Illness Therapy-Fatigue is a reliable and valid measure in patients with active ankylosing spondylitis. J Patient Rep Outcomes. 2022 Sep 23;6(1):100. doi: 10.1186/s41687-022-00508-0.

Reference Type DERIVED
PMID: 36138330 (View on PubMed)

Navarro-Compan V, Wei JC, Van den Bosch F, Magrey M, Wang L, Fleishaker D, Cappelleri JC, Wang C, Wu J, Dina O, Fallon L, Strand V. Effect of tofacitinib on pain, fatigue, health-related quality of life and work productivity in patients with active ankylosing spondylitis: results from a phase III, randomised, double-blind, placebo-controlled trial. RMD Open. 2022 Jun;8(2):e002253. doi: 10.1136/rmdopen-2022-002253.

Reference Type DERIVED
PMID: 35654457 (View on PubMed)

Deodhar A, Sliwinska-Stanczyk P, Xu H, Baraliakos X, Gensler LS, Fleishaker D, Wang L, Wu J, Menon S, Wang C, Dina O, Fallon L, Kanik KS, van der Heijde D. Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2021 Aug;80(8):1004-1013. doi: 10.1136/annrheumdis-2020-219601. Epub 2021 Apr 27.

Reference Type DERIVED
PMID: 33906853 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Related Links

Access external resources that provide additional context or updates about the study.

https://pmiform.com/clinical-trial-info-request?StudyID=A3921120

To obtain contact information for a study center near you, click here.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

AS

Identifier Type: OTHER

Identifier Source: secondary_id

2018-000226-58

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

A3921120

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.